{"entity":{"id":"paper-prior-cancer-res","kind":"paper","name":"The Frequency of Ras Mutations in Cancer","aka":[],"tldr":"Paper cited by one bottleneck page, indexed on Europe PMC as PubMed record 32209560 and published in Cancer Research; the citing page links this DOI, which is how the record was matched.","summary":"Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regarding the cancer mutation frequency of Ras, with quoted values varying from 10%-30%. This variability is at least in part due to the selective aggregation of data from different databases and the dominant influence of particular cancer types and particular Ras isoforms within these datasets. To provide a more definitive figure for Ras mutation frequency in cancer, we cross-referenced the data in all major publicly accessible cancer mutation databases to determine reliable mutation frequency values for each Ras isoform in all major cancer types. These percentages were then applied to current U.S. cancer incidence statistics to estimate the number of new patients each year that have Ras-mutant cancers. We find that approximately 19% of patients with cancer harbor Ras mutations, equivalent to approximately 3.4 million new cases per year worldwide. We discuss the Ras isoform and mutation-specific trends evident within the datasets that are relevant to current Ras-targeted therapies.\n\nIndexed on Europe PMC as PubMed record 32209560 (DOI 10.1158/0008-5472.can-19-3682). Matched by DOI alone: one bottleneck page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Cancer Res 2020","url":"https://doi.org/10.1158/0008-5472.can-19-3682"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32209560/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/32209560"}],"tags":["europepmc-ingest"],"related":["b-undruggable-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-research"],"dependsOn":[],"notes":[],"journal":"Cancer Research","year":2020,"doi":"10.1158/0008-5472.can-19-3682","pmid":"32209560","authors":"Prior IA, Hood FE, Hartley JL","paperType":"review","findings":[],"whatItMeans":"One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-prior-cancer-res/","neighbours":{"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"journal":[{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/"}]}}